AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Rao Srinivas sold (to issuer) 212,942 shares of ATAI

Rao Srinivas (See remarks) sold (to issuer) 212,942 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Original reporting
SEC EDGAR · Rao Srinivas
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Bearish
medium confidence
Mentioned
$ATAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAIBearishLow
01

Why it matters

The filing provides the first public disclosure of Rao Srinivas's complete divestiture from ATAI.

02

Market read

Primary insider sale disclosure; modest relevance for traders monitoring insider activity.

03

What to watch

Lack of disclosed price prevents assessment of monetary value; insider may have tax or personal reasons.

Relevance 4/10Novelty 4/10Timing: filed 2026-09-11

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ATAIBearishMedium confidence
Context

Officer/director Rao Srinivas sold his entire 212,942-share holding, leaving 0 shares after the transaction.

Expected impact

Potential modest downside pressure as the market digests the insider divestment.

Evidence & confidence

While the sale size is modest and price undisclosed, a complete exit by an officer can be viewed negatively by investors.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated insider transaction.

Regional

No significant regional effect.

Global

Limited to ATAI investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Company
    AtaiBeckley Inc.

    Biotech company listed on NASDAQ under ticker ATAI.

  • Individual
    Rao Srinivas

    Officer and director of AtaiBeckley Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min